# A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

> **NCT04522375** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Foresee Pharmaceuticals Co., Ltd.**

## Conditions studied

- Fanconi Anemia

## Interventions

- **DRUG:** FP-045

## Key facts

- **NCT ID:** NCT04522375
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-30
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Twenty months after investigative site initiations, and best efforts to identify study participants, no participants were identified.
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522375, "A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04522375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*